PL2379086T3 - Preparat farmeceutyczny - Google Patents

Preparat farmeceutyczny

Info

Publication number
PL2379086T3
PL2379086T3 PL09795982T PL09795982T PL2379086T3 PL 2379086 T3 PL2379086 T3 PL 2379086T3 PL 09795982 T PL09795982 T PL 09795982T PL 09795982 T PL09795982 T PL 09795982T PL 2379086 T3 PL2379086 T3 PL 2379086T3
Authority
PL
Poland
Prior art keywords
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
PL09795982T
Other languages
English (en)
Inventor
Hendrik Jan Ankersmit
Original Assignee
Aposcience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aposcience Ag filed Critical Aposcience Ag
Publication of PL2379086T3 publication Critical patent/PL2379086T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09795982T 2008-12-18 2009-12-18 Preparat farmeceutyczny PL2379086T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08450199A EP2201954A1 (en) 2008-12-18 2008-12-18 Pharmaceutical preparation
PCT/EP2009/067536 WO2010070105A1 (en) 2008-12-18 2009-12-18 Pharmaceutical preparation
EP09795982.9A EP2379086B1 (en) 2008-12-18 2009-12-18 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
PL2379086T3 true PL2379086T3 (pl) 2016-01-29

Family

ID=41381669

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09795982T PL2379086T3 (pl) 2008-12-18 2009-12-18 Preparat farmeceutyczny

Country Status (14)

Country Link
US (2) US10478456B2 (pl)
EP (2) EP2201954A1 (pl)
JP (1) JP5869344B2 (pl)
CN (1) CN102316879B (pl)
AU (1) AU2009329544B2 (pl)
CA (1) CA2747207C (pl)
DK (1) DK2379086T3 (pl)
ES (1) ES2554624T3 (pl)
HU (1) HUE028152T2 (pl)
NZ (1) NZ593365A (pl)
PL (1) PL2379086T3 (pl)
RU (1) RU2542512C2 (pl)
WO (1) WO2010070105A1 (pl)
ZA (1) ZA201104348B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
CN102438635B (zh) * 2009-03-05 2014-09-17 马克罗柯尔有限公司 活化的白细胞组合物
CA2893962C (en) * 2012-12-06 2021-04-06 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
PT2941257T (pt) 2013-01-07 2018-03-06 Univ Franche Comte Terapia de doença utilizando uma preparação farmacêutica tolerogénica
WO2015120077A1 (en) * 2014-02-04 2015-08-13 Gonzalez Jose Javier Lopez Biologically optimized adult mesenchymal stem cells
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
EP3502692A1 (en) 2017-12-20 2019-06-26 Aposcience AG Potency assay for secretomes
EP3842064A1 (en) 2019-12-23 2021-06-30 Aposcience AG Composition for treating or preventing an allergy or allergic reaction
EP4074320A1 (en) 2021-04-13 2022-10-19 Aposcience AG Treatment of skin scars
EP4197547A1 (en) * 2021-12-20 2023-06-21 Aposcience AG Composition for treating or preventing vasculitis and diseases associated with vasculitis
WO2024105193A1 (en) * 2022-11-17 2024-05-23 Koptyug Andrey V Novel compounds and methods
WO2024227265A1 (en) 2023-05-03 2024-11-07 Volumina Medical Sa Devices and methods for preparing and conditioning biological assemblies for minimally invasive delivery for tissue engineering, cell therapies and other therapeutic applications
EP4628570A1 (en) 2024-04-03 2025-10-08 Aposcience AG Method for cultivating mammalian cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080600B1 (fr) * 1981-11-27 1985-06-19 Firmenich Sa Utilisation de 2-hydroxy-3,4,4-triméthyl-cyclopent-2-ène-1-one à titre d'ingrédient odoriférant
JP2005530768A (ja) * 2002-05-09 2005-10-13 メディジーンズ 血漿または血清を含有した創傷治療用医薬組成物
US20070110737A1 (en) * 2003-12-29 2007-05-17 Allan Mishra Compositions and method for decreasing the appearance of skin wrinkles
RU2262941C2 (ru) * 2004-01-05 2005-10-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ иммунотерапии злокачественных опухолей головного мозга
EP1737949B1 (en) * 2004-03-09 2010-09-15 Absorber AB Endothelial progenitor cells and methods of use thereof
WO2005123107A2 (en) * 2004-06-09 2005-12-29 Research Development Foundation Immune response suppressor and treatment of multiple sclerosis
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
CN100552022C (zh) * 2004-09-20 2009-10-21 上海市第一人民医院 一种诱导分化人外周血单个核细胞的方法
EA200800123A1 (ru) * 2005-06-24 2008-12-30 Кадила Хелзкэр Лимитед Пептиды, производные тромбоспондина-1, и способы лечения
JP2009535412A (ja) * 2006-05-03 2009-10-01 セラコス・インコーポレイテッド ストレス関連疾患および症状を伴う疾患を治療するための方法

Also Published As

Publication number Publication date
JP2012512843A (ja) 2012-06-07
EP2379086B1 (en) 2015-09-02
US20110250190A1 (en) 2011-10-13
EP2201954A1 (en) 2010-06-30
US10478456B2 (en) 2019-11-19
CA2747207C (en) 2017-11-21
ZA201104348B (en) 2012-02-29
NZ593365A (en) 2012-11-30
RU2542512C2 (ru) 2015-02-20
US20200254019A1 (en) 2020-08-13
AU2009329544B2 (en) 2015-01-22
JP5869344B2 (ja) 2016-02-24
BRPI0922173A2 (pt) 2015-12-29
EP2379086A1 (en) 2011-10-26
HUE028152T2 (en) 2016-11-28
DK2379086T3 (en) 2015-10-05
AU2009329544A1 (en) 2011-07-07
CN102316879B (zh) 2014-01-22
RU2011129672A (ru) 2013-01-27
CN102316879A (zh) 2012-01-11
ES2554624T3 (es) 2015-12-22
WO2010070105A1 (en) 2010-06-24
CA2747207A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
CY2018030I2 (el) Φαρμακοτεχνικη μορφη 514
BRPI0920521A2 (pt) combinação farmacêutica
PL3072906T3 (pl) Preparat przeciwciała
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0912213A2 (pt) preparação cosmética
BRPI0807453A2 (pt) Preparação sólida
SMT201400069B (it) Formulazione farmaceutica
EP2351549A4 (en) INTERCONNECTS
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0912026A2 (pt) formulação homeopática
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
BRPI0921654A2 (pt) formulação farmacêutica
DK2285357T3 (da) Farmaceutisk sammensætning omfattende brivaracetam
BRPI1015939A2 (pt) composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
DK2125048T3 (da) Præparat
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921313A2 (pt) composição farmaucêutica
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0922653A2 (pt) preparação farmacêutica